Exosens Shares Surge Over 7% After Annual Results Exceed Expectations
Exosens shares soared this Tuesday at midday, driven by the announcement of its 2025 annual results which surpassed the group's targets. The share price reached 59.70 euros, up by 7.37% from the previous day. Following this, TP Icap Midcap significantly raised its price target for the stock.
The detection and imaging technology specialist Exosens revealed its 2025 annual accounts on Monday evening, reporting a consolidated revenue of 468.2 million euros, which is an increase of 22.1% year-over-year. This performance exceeds the management's stated ambitions and reflects a strong commercial momentum, particularly in the defense and night vision segments. The market response was swift: the stock gained more than 7% by Tuesday mid-session. Over the year, the valuation has nearly multiplied by 2.5, with a cumulative increase of 149.8%. The next meeting with investors is scheduled for April 27, when the results for the first quarter of 2026 will be published.
TP Icap Midcap Raises Price Target Following Results
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Following these announcements, TP Icap Midcap revised its price target upwards from 52 to 65 euros, along with a buy recommendation. This new target represents a potential increase of about 8.9% compared to the current price of 59.70 euros, indicating renewed confidence in the group's trajectory. Technically, today's session brings the stock directly in contact with its resistance at 60.50 euros. A sustained breakthrough of this threshold could pave the way for new levels. The stock is now well above its 50-day moving average of 53.03 euros, confirming the bullish trend that has been in place for several weeks. The RSI, at 55, remains in the neutral zone, indicating that the stock is not yet in an overbought situation despite the recent acceleration.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
